Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

Name: Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis
Creator: Daniel S. Alicea, MS
Published: 2024-11-11T20:51:27.121Z
Keywords: Dermatology, Oncology

Alicea, MS, Daniel S.; Miao, PharmD, MD, Emily; Ch'en, BS, Peter; Tuckman, MBA, Steven W.; Ohri, MD, MS, Nitin; Halmos, MD, Balazs; Cheng, MD, PhD, Haiying; Lee, MD, MPH, Matthew; McLellan, MD, Beth N.

doi:10.17632/pnb8kwtfh2.1

Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

Published: 11 November 2024| Version 1 | DOI: 10.17632/pnb8kwtfh2.1

Contributors:

Daniel S. Alicea, MS,

,

Description

An additional Kaplan-Meier curve seen in supplemental Figure 1 was conducted to assess overall survival among groups with and without the development of a cutaneous treatment related adverse event; results showed similar survival among the groups (p=0.960).

Files

Steps to reproduce

Kaplan-Meier curves were generated for overall survival and log-rank test compared the curves between patients with and without the development of a cutaneous TRAE.

Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

Description

Files

Steps to reproduce

Categories

Licence